Search

Cancer often leaves those it touches consumed with a feeling of hopelessness. But sometimes that feeling can motivate clinicians, patients, and supporters alike to turn soul-crushing moments into positive change.

… Thursday, January 27, 2022 Cancer often leaves those it touches consumed with a feeling of hopelessness. But sometimes that feeling can motivate clinicians, patients, and supporters alike to turn soul-crushing moments into positive change. Dave Linn and Jennifer Goodman Linn used their experience with

Patients with inoperable advanced liver cancer have a new option for treatment to extend their lives.

… Monday, October 24, 2022 Patients with inoperable advanced liver cancer have a new option for treatment to extend their lives. Today the U.S. Food and Drug Administration (FDA) approved a combination of the immunotherapy drugs durvalumab (Imfinzi®) plus the experimental drug tremelimumab for people with

Learn about some of the most important clinical advances made at MSK in 2021.

… Wednesday, December 22, 2021 In 2021, Memorial Sloan Kettering Cancer Center doctors and scientists continued to make major discoveries that will improve the treatment of cancer. Philanthropic donations provided critical support for much of this research, allowing clinical researchers to pursue innovative

Long-awaited results of clinical trials testing targeted drugs and immunotherapy combinations were on offer at the annual American Association for Cancer Research (AACR) conference.

… Monday, April 18, 2016 Summary MSK scientists featured prominently in the opening days of the annual AACR conference, held this year in New Orleans. They presented new data from clinical trials of both targeted drugs and immunotherapies, and were recognized for their scientific accomplishments. Highlights

The David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center will be home to the largest gathering of hematologic experts ever at Memorial Sloan Kettering Cancer Center (MSK), including specialists in blood and marrow stem cell transplants, chimeric antigen receptor T cell therapy, lymphoma, leukemia, multiple myeloma, and nonmalignant blood disorders.

… Tuesday, December 10, 2019 The David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center will be home to the largest gathering of hematologic experts ever at Memorial Sloan Kettering Cancer Center (MSK), including specialists in blood and marrow stem cell transplants, chimeric antigen

The 2023 GSK Chairman’s Prize recognizes Chi Nguyen for research on gut health.

… Tuesday, August 15, 2023 Chi Nguyen , a PhD student attending the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK) , has been awarded the 2023 Chairman’s Prize. The competitive award is presented annually and was established by GSK’s Board of Trustees Chair Emeritus Louis V. Gerstner

New data from researchers at Memorial Sloan Kettering Cancer Center (MSK) revealed the effects of Medicaid expansion on cancer death rates on a national scale.

… Wednesday, May 13, 2020 New data from researchers at Memorial Sloan Kettering Cancer Center (MSK) revealed the effects of Medicaid expansion on cancer death rates on a national scale. The landmark study found that states that adopted Medicaid expansion following the passage of the Affordable Care Act

Memorial Sloan Kettering Cancer Center (MSK) is proud to announce that two Sloan Kettering Institute (SKI) researchers have been named 2022 Marie-Josée Kravis WISE fellowship grant recipients.

… Wednesday, March 23, 2022 Memorial Sloan Kettering Cancer Center (MSK) is proud to announce that two Sloan Kettering Institute (SKI) researchers have been named 2022 Marie-Josée Kravis (WISE) fellowship grant recipients. The Kravis WISE Symposium is held every year during Women’s History Month in March

As long-term cancer survival outcomes improve, the brain has increasingly become a site of refractory and recurrent disease.

… Thursday, May 22, 2025 As long-term cancer survival outcomes improve, the brain has increasingly become a site of refractory and recurrent disease. At Memorial Sloan Kettering Cancer Center (MSK),  neurosurgeon Nelson Moss, MD , Co-Director of the  Multidisciplinary Brain Metastasis Program , and  radiation

Sloan Kettering Institute investigators are taking important steps toward being able to identify all the cell types in tumors. With this information, they can figure out how the cells work together.

… Thursday, June 28, 2018 Summary Sloan Kettering Institute investigators are laying the groundwork for research into the different cell types in found in and around tumors. The composition of malignant tumors is incredibly complex. They contain not only cancer cells but also dozens of other cell types